Nadeem Qureshi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9531256/publications.pdf

Version: 2024-02-01

110 papers	4,368 citations	147801 31 h-index	123424 61 g-index
112 all docs	112 docs citations	112 times ranked	6554 citing authors

#	Article	IF	Citations
1	Can machine-learning improve cardiovascular risk prediction using routine clinical data?. PLoS ONE, 2017, 12, e0174944.	2.5	814
2	Achieving change in primary careâ€"causes of the evidence to practice gap: systematic reviews of reviews. Implementation Science, 2015, 11, 40.	6.9	316
3	Family History in Public Health Practice: A Genomic Tool for Disease Prevention and Health Promotion. Annual Review of Public Health, 2010, 31, 69-87.	17.4	264
4	Family history of type 2 diabetes: A population-based screening tool for prevention?. Genetics in Medicine, 2006, 8, 102-108.	2.4	167
5	The new genetics and primary care: GPs' views on their role and their educational needs. Family Practice, 1999, 16, 420-425.	1.9	158
6	Achieving change in primary careâ€"effectiveness of strategies for improving implementation of complex interventions: systematic review of reviews. BMJ Open, 2015, 5, e009993.	1.9	153
7	The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Medicine, 2019, 17, 145.	5.5	151
8	Effect of Adding Systematic Family History Enquiry to Cardiovascular Disease Risk Assessment in Primary Care. Annals of Internal Medicine, 2012, 156, 253.	3.9	94
9	Using family history information to promote healthy lifestyles and prevent diseases; a discussion of the evidence. BMC Public Health, 2010, 10, 248.	2.9	89
10	Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart, 2019, 105, 975-981.	2.9	86
11	The current state of cancer family history collection tools in primary care: a systematic review. Genetics in Medicine, 2009, 11, 495-506.	2.4	85
12	Improving identification of familial hypercholesterolaemia in primary care: Derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis, 2015, 238, 336-343.	0.8	83
13	Prediction of premature all-cause mortality: A prospective general population cohort study comparing machine-learning and standard epidemiological approaches. PLoS ONE, 2019, 14, e0214365.	2.5	79
14	Collecting genetic information in primary care: evaluating a new family history tool. Family Practice, 2005, 22, 663-669.	1.9	72
15	Systematic review: family history in risk assessment for common diseases. Annals of Internal Medicine, 2009, 151, 878-85.	3.9	67
16	A review of clinical practice guidelines found that they were often based on evidence of uncertain relevance to primary care patients. Journal of Clinical Epidemiology, 2014, 67, 1251-1257.	5.0	65
17	What hinders minority ethnic access to cancer genetics services and what may help?. European Journal of Human Genetics, 2014, 22, 866-874.	2.8	61
18	Identification and management of familial hypercholesterolaemia: what does it mean to primary care?. British Journal of General Practice, 2009, 59, 773-778.	1.4	59

#	Article	IF	Citations
19	The effects of preconception interventions on improving reproductive health and pregnancy outcomes in primary care: A systematic review. European Journal of General Practice, 2016, 22, 42-52.	2.0	55
20	Raising the profile of genetics in primary care. Nature Reviews Genetics, 2004, 5, 783-790.	16.3	51
21	The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment. Open Heart, 2015, 2, e000272.	2.3	51
22	Parentsâ€™ responses to receiving sickle cell or cystic fibrosis carrier results for their child following newborn screening. European Journal of Human Genetics, 2015, 23, 459-465.	2.8	46
23	Cardiovascular risk assessment and lipid modification: NICE guideline. British Journal of General Practice, 2015, 65, 378-380.	1.4	42
24	â€˜Over-the-counterâ€™ genetic testing: what does it really mean for primary care?. British Journal of General Practice, 2009, 59, 283-287.	1.4	41
25	Informing patients of familial diabetes mellitus risk: How do they respond? A cross-sectional survey. BMC Health Services Research, 2008, 8, 37.	2.2	40
26	Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part. Atherosclerosis, 2018, 277, 399-406.	0.8	38
27	Collection and use of cancer family history in primary care. Evidence Report/technology Assessment, 2007, , 1-84.	1.3	38
28	Detection of familial hypercholesterolaemia: external validation of the FAMCAT clinical case-finding algorithm to identify patients in primary care. Lancet Public Health, The, 2019, 4, e256-e264.	10.0	37
29	What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). BMC Cancer, 2020, 20, 570.	2.6	37
30	Automated Software System to Promote Anticoagulation and Reduce Stroke Risk. Stroke, 2017, 48, 787-790.	2.0	33
31	Perspectives on enhancing physical activity and diet for health promotion among at-risk urban UK South Asian communities: a qualitative study. BMJ Open, 2015, 5, e007317-e007317.	1.9	32
32	Availability and Quality of Coronary Heart Disease Family History in Primary Care Medical Records: Implications for Cardiovascular Risk Assessment. PLoS ONE, 2014, 9, e81998.	2.5	32
33	Imparting carrier status results detected by universal newborn screening for sickle cell and cystic fibrosis in England: a qualitative study of current practice and policy challenges. BMC Health Services Research, 2007, 7, 203.	2.2	31
34	GPs' opinions of their role in prenatal genetic services: a cross-sectional survey. Family Practice, 2006, 23, 106-110.	1.9	30
35	Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trialâ€“a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25Âmg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials, 2014, 15, 169.	1.6	29
36	Sex, Age, and Socioeconomic Differences in Nonfatal Stroke Incidence and Subsequent Major Adverse Outcomes. Stroke, 2021, 52, 396-405.	2.0	28

#	Article	IF	Citations
37	Effectiveness of physical activity and dietary interventions in South Asian populations: a systematic review. British Journal of General Practice, 2013, 63, e104-e114.	1.4	27
38	Venous thromboembolism in adults screened for sickle cell trait: a population-based cohort study with nested caseâ€“control analysis. BMJ Open, 2017, 7, e012665.	1.9	27
39	Inclusion of diverse populations in genomic research and health services: Genomix workshop report. Journal of Community Genetics, 2017, 8, 267-273.	1.2	26
40	Making sense of being at â€˜high riskâ€™ of coronary heart disease within primary prevention. Psychology and Health, 2010, 25, 289-304.	2.2	25
41	Assessing family history of heart disease in primary care consultations: a qualitative study. Family Practice, 2007, 24, 435-442.	1.9	24
42	Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study. Atherosclerosis, 2019, 287, 8-15.	0.8	24
43	Feasibility of improving identification of familial hypercholesterolaemia in general practice: intervention development study. BMJ Open, 2016, 6, e011734.	1.9	23
44	Long-term body mass index changes in overweight and obese adults and the risk of heart failure, cardiovascular disease and mortality: a cohort study of over 260,000 adults in the UK. BMC Public Health, 2021, 21, 576.	2.9	23
45	The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women. BMC Cancer, 2020, 20, 452.	2.6	23
46	Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales. Atherosclerosis, 2018, 275, 80-87.	0.8	21
47	Engagement barriers and service inequities in the NHS Breast Screening Programme: Views from British-Pakistani women. Journal of Medical Screening, 2020, 27, 130-137.	2.3	21
48	Performance and clinical utility of supervised machine-learning approaches in detecting familial hypercholesterolaemia in primary care. Npj Digital Medicine, 2020, 3, 142.	10.9	21
49	Informing Children of Their Newborn Screening Carrier Result for Sickle Cell or Cystic Fibrosis: Qualitative Study of Parentsâ€™ Intentions, Views and Support Needs. Journal of Genetic Counseling, 2014, 23, 409-420.	1.6	20
50	Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records. Atherosclerosis, 2020, 315, 131-137.	0.8	19
51	Beyond beliefs: risk assessment technologies shaping patientsâ€™ experiences of heart disease prevention. Sociology of Health and Illness, 2012, 34, 560-575.	2.1	18
52	Addressing the evidence to practice gap for complex interventions in primary care: a systematic review of reviews protocol. BMJ Open, 2014, 4, e005548-e005548.	1.9	17
53	Improving identification and management of familial hypercholesterolaemia in primary care: Pre- and post-intervention study. Atherosclerosis, 2018, 274, 54-60.	0.8	17
54	Obesity and longâ€term outcomes after incident stroke: a prospective populationâ€based cohort study. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 2111-2121.	7.3	17

#	Article	IF	Citations
55	Predicting major adverse cardiovascular events for secondary prevention: protocol for a systematic review and meta-analysis of risk prediction models. BMJ Open, 2020, 10, e034564.	1.9	16
56	Does bone mineral density improve the predictive accuracy of fracture risk assessment? A prospective cohort study in Northern Denmark. BMJ Open, 2018, 8, e018898.	1.9	15
57	Does the evidence referenced in NICE guidelines reflect a primary care population?. British Journal of General Practice, 2011, 61, e112-e117.	1.4	14
58	Familial influences on antenatal and newborn haemoglobinopathy screening. Ethnicity and Health, 2011, 16, 361-375.	2.5	14
59	Primary care evidence in clinical guidelines: a mixed methods study of practitionersâ€™ views. British Journal of General Practice, 2014, 64, e719-e727.	1.4	14
60	Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. The Cochrane Library, 2018, 3, CD010849.	2.8	14
61	Using electronic health records to quantify and stratify the severity of type 2 diabetes in primary care in England: rationale and cohort study design. BMJ Open, 2018, 8, e020926.	1.9	14
62	The genetics liaison nurse role as a means of educating and supporting primary care professionals. Family Practice, 2002, 19, 193-196.	1.9	13
63	Subjective vision and hearing impairment and falls among community-dwelling adults: a prospective study in the Survey of Health, Ageing and Retirement in Europe (SHARE). European Geriatric Medicine, 2021, 12, 1031-1043.	2.8	13
64	Pharmacogenomic testing to support prescribing in primary care: a structured review of implementation models. Pharmacogenomics, 2021, 22, 761-776.	1.3	13
65	Using web-based familial risk information for diabetes prevention: a randomized controlled trial. BMC Public Health, 2013, 13, 485.	2.9	12
66	Introducing genetic testing for cardiovascular disease in primary care: a qualitative study. British Journal of General Practice, 2014, 64, e282-e289.	1.4	12
67	Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. The Cochrane Library, 2015, , CD010849.	2.8	12
68	Screening for Familial Hypercholesterolemia in Children: What Can We Learn From Adult Screening Programs?. Healthcare (Switzerland), 2015, 3, 1018-1030.	2.0	12
69	Realising the potential of the family history in risk assessment and primary prevention of coronary heart disease in primary care: ADDFAM study protocol. BMC Health Services Research, 2009, 9, 184.	2.2	11
70	A systematic review of educational outreach visits for non-prescribing interventions in general practice. European Journal of General Practice, 2002, 8, 31-36.	2.0	10
71	Consanguinity and genetic morbidity in a British primary care setting: a pilot study with trained linkworkers. Annals of Human Biology, 2003, 30, 140-147.	1.0	10
72	Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care. Open Heart, 2021, 8, e001817.	2.3	10

#	Article	IF	Citations
73	Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care. Open Heart, 2021, 8, e001752.	2.3	10
74	AUtomated Risk Assessment for Stroke in Atrial Fibrillation (AURAS-AF) - an automated software system to promote anticoagulation and reduce stroke risk: study protocol for a cluster randomised controlled trial. Trials, 2013, 14, 385.	1.6	9
75	Improving primary care identification of familial breast cancer risk using proactive invitation and decision support. Familial Cancer, 2021, 20, 13-21.	1.9	9
76	Sex disparity in subsequent outcomes in survivors of coronary heart disease. Heart, 2022, 108, 37-45.	2.9	9
77	Case-finding and genetic testing for familial hypercholesterolaemia in primary care. Heart, 2021, 107, 1956-1961.	2.9	9
78	Cost-Effectiveness of Screening Algorithms for Familial Hypercholesterolaemia in Primary Care. Journal of Personalized Medicine, 2022, 12, 330.	2.5	9
79	Leaders, leadership and future primary care clinical research. BMC Family Practice, 2008, 9, 52.	2.9	8
80	Development and validation of the DIabetes Severity SCOre (DISSCO) in 139 626 individuals with type 2 diabetes: a retrospective cohort study. BMJ Open Diabetes Research and Care, 2020, 8, e000962.	2.8	8
81	Evaluating a clinical tool (FAMCAT) for identifying familial hypercholesterolaemia in primary care: a retrospective cohort study. BJGP Open, 2020, 4, bjgpopen20X101114.	1.8	8
82	Understanding the barriers and enablers of pharmacogenomic testing in primary care: a qualitative systematic review with meta-aggregation synthesis. Pharmacogenomics, 2022, 23, 135-154.	1.3	8
83	How does a simple enquiry compare to a detailed family history questionnaire to identify coronary heart disease or diabetic familial risk?. Genetics in Medicine, 2011, 13, 443-446.	2.4	7
84	How genomic information is accessed in clinical practice: an electronic survey of UK general practitioners. Journal of Community Genetics, 2020, 11, 377-386.	1.2	7
85	Genomic medicine for underserved minority populations in family medicine. American Family Physician, 2005, 72, 386-7.	0.1	7
86	Barriers to a software reminder system for risk assessment of stroke in atrial fibrillation: a process evaluation of a cluster randomised trial in general practice. British Journal of General Practice, 2018, 68, e844-e851.	1.4	6
87	Effectiveness of interventions to identify and manage patients with familial cancer risk in primary care: a systematic review. Journal of Community Genetics, 2020, 11, 73-83.	1.2	6
88	Risk prediction of new AF: is there a role for artificial intelligence?. European Journal of Preventive Cardiology, 2020, 27, 1325-1327.	1.8	6
89	Breast Cancer Genetics in Primary CareWhich GPs Most Accurately Categorise Patients at Low Risk?. European Journal of General Practice, 2002, 8, 146-150.	2.0	5
90	Dealing with family history of breast cancer: something new, something old. British Journal of General Practice, 2014, 64, 6-7.	1.4	5

#	Article	IF	Citations
91	Personalised medicine in general practice: the example of raised cholesterol. British Journal of General Practice, 2018, 68, 68-69.	1.4	5
92	Systematic Identification of Familial Hypercholesterolaemia in Primary Careâ€"A Systematic Review. Journal of Personalized Medicine, 2021, 11, 302.	2.5	4
93	Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: A systematic review and meta-analysis. Atherosclerosis, 2021, 338, 7-14.	0.8	4
94	Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. The Cochrane Library, 2021, 2021, CD010849.	2.8	4
95	Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease. PLoS ONE, 2021, 16, e0260839.	2.5	4
96	LDL cholesterol response to statins and future risk of cardiovascular disease. Heart, 2019, 105, 1290.3-1291.	2.9	3
97	Secondary prevention of cardiovascular disease: Time to rethink stratification of disease severity?. European Journal of Preventive Cardiology, 2019, 26, 1778-1780.	1.8	3
98	Is family history still underutilised? Exploring the views and experiences of primary care doctors in Malaysia. Journal of Community Genetics, 2020, 11, 413-420.	1.2	3
99	Introducing genetic testing with case finding for familial hypercholesterolaemia in primary care: qualitative study of patient and health professional experience. British Journal of General Practice, 2022, 72, e519-e527.	1.4	3
100	Genetic profiling in primary care can enhance personalized drug therapy: reality or myth?. Personalized Medicine, 2008, 5, 311-316.	1.5	2
101	Early identification of familial hypercholesterolaemia in general practice using patient-specific reminders: focus group with General Practitioners. BMC Health Services Research, 2014, 14, .	2.2	2
102	Prioritizing health outcomes in a limited world. Current Opinion in Lipidology, 2015, 26, 188-194.	2.7	2
103	The role of cost-effectiveness analysis in the development of indicators to support incentive-based behaviour in primary care in England. Journal of Health Services Research and Policy, 2016, 21, 263-271.	1.7	2
104	Specialist recommendation for chemoprevention medications in patients at familial risk of breast cancer: a cross-sectional survey in England. Journal of Community Genetics, 2021, 12, 111-120.	1.2	2
105	Hiding in plain sight: supporting primary care to find familial hypercholesterolaemia and save lives. Heart, 2021, 107, 1190-1192.	2.9	2
106	Strategies for screening for familial hypercholesterolaemia in primary care and other community settings. The Cochrane Library, 2021, 2021, CD012985.	2.8	2
107	Comparison of coronary heart disease genetic assessment with conventional cardiovascular risk assessment in primary care: reflections on a feasibility study. Primary Health Care Research and Development, 2015, 16, 607-617.	1.2	1
108	Strategies for identifying familial hypercholesterolaemia in non-specialist clinical settings. The Cochrane Library, 0, , .	2.8	1

#	Article	IF	Citations
109	Characteristics predicting recommendation for familial breast cancer referral in a cohort of women from primary care. Journal of Community Genetics, 2020, 11, 331-338.	1.2	0
110	Assessing the severity of cardiovascular disease in 213 088 patients with coronary heart disease: a retrospective cohort study. Open Heart, 2021, 8, e001498.	2.3	0